JP3717962B2 - Method for producing glyceroglycolipid compound - Google Patents
Method for producing glyceroglycolipid compound Download PDFInfo
- Publication number
- JP3717962B2 JP3717962B2 JP05452495A JP5452495A JP3717962B2 JP 3717962 B2 JP3717962 B2 JP 3717962B2 JP 05452495 A JP05452495 A JP 05452495A JP 5452495 A JP5452495 A JP 5452495A JP 3717962 B2 JP3717962 B2 JP 3717962B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- reaction
- structural formula
- solvent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 53
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 239000002904 solvent Substances 0.000 claims description 27
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 15
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 15
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 11
- 229950004354 phosphorylcholine Drugs 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 9
- 238000005984 hydrogenation reaction Methods 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 description 86
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- -1 lipid compound Chemical class 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- IMXUMYOWTYJMEV-FMQGQQCHSA-N [(2s)-2-hydroxy-3-[(2s,3r,4s,5r,6r)-6-(hydroxymethyl)-3,4,5-tris(phenylmethoxy)oxan-2-yl]oxypropyl] hexadecanoate Chemical compound O([C@@H]1[C@@H](CO)O[C@@H]([C@@H]([C@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)OC[C@H](O)COC(=O)CCCCCCCCCCCCCCC)CC1=CC=CC=C1 IMXUMYOWTYJMEV-FMQGQQCHSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229960001701 chloroform Drugs 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000005270 trialkylamine group Chemical group 0.000 description 4
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 2
- PJGSXAZUFMCQKA-UHFFFAOYSA-N 1-bromo-2-dichlorophosphorylethane Chemical compound ClP(Cl)(=O)CCBr PJGSXAZUFMCQKA-UHFFFAOYSA-N 0.000 description 2
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 description 2
- 239000012433 hydrogen halide Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229910001958 silver carbonate Inorganic materials 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UWHSPZZUAYSGTB-UHFFFAOYSA-N 1,1,3,3-tetraethylurea Chemical compound CCN(CC)C(=O)N(CC)CC UWHSPZZUAYSGTB-UHFFFAOYSA-N 0.000 description 1
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- YRTAUZXAHQPFJV-UHFFFAOYSA-N 1-chloro-2-dichlorophosphoryloxyethane Chemical compound ClCCOP(Cl)(Cl)=O YRTAUZXAHQPFJV-UHFFFAOYSA-N 0.000 description 1
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FHDAGNAMIMHCJQ-UHFFFAOYSA-N C(CI)P(=O)(Cl)Cl Chemical compound C(CI)P(=O)(Cl)Cl FHDAGNAMIMHCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202952 Mycoplasma fermentans Species 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PGUUMXDUQJIEQK-HLVREVBOSA-N [(2S)-2-hexadecanoyloxy-3-[(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-3,4,5-tris(phenylmethoxy)oxan-2-yl]oxypropyl] hexadecanoate Chemical compound O([C@@H]1[C@@H](CO)O[C@@H]([C@@H]([C@H]1OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)CC1=CC=CC=C1 PGUUMXDUQJIEQK-HLVREVBOSA-N 0.000 description 1
- AOZUYISQWWJMJC-UHFFFAOYSA-N acetic acid;methanol;hydrate Chemical compound O.OC.CC(O)=O AOZUYISQWWJMJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- XXJVRVRVOQTORH-UHFFFAOYSA-M cesium;hexadecanoate Chemical compound [Cs+].CCCCCCCCCCCCCCCC([O-])=O XXJVRVRVOQTORH-UHFFFAOYSA-M 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 150000002812 neutral glycosphingolipids Chemical class 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- PZKNFJIOIKQCPA-UHFFFAOYSA-N oxalic acid palladium Chemical compound [Pd].OC(=O)C(O)=O PZKNFJIOIKQCPA-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- PQZWQGNQOVDTRF-UHFFFAOYSA-N pentadecanoyl chloride Chemical compound CCCCCCCCCCCCCCC(Cl)=O PQZWQGNQOVDTRF-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- LPWCRLGKYWVLHQ-UHFFFAOYSA-N tetradecanoyl chloride Chemical compound CCCCCCCCCCCCCC(Cl)=O LPWCRLGKYWVLHQ-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Saccharide Compounds (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、マイコプラズマ・フェルメンタンス(Mycoplasma fermentans)−HTLV−I(Human T-lymphotropic virus type I) に重複感染したヒトヘルパーT細胞の脂質画分から見出された新規な『ホスホリルコリン含有α−グルコース(糖)脂質化合物』を新たに化学的に合成する方法、並びに、その合成法における新規な中間体化合物を提供するものである。
【0002】
【従来技術の説明】
従来からウイルス感染によって細胞の糖脂質糖鎖に大きな変化が生じることが知られていた。ヒトレトロウイルスであるHTLV−I、およびHIV(human immunodeficiency virus)はいずれもリンパ球のなかでもとくにヘルパーT細胞に感染しやすく、HTLV−Iではこれをモノクローナルに腫瘍化し、HIVではこれを破壊することにより発症する。
【0003】
これらのウイルス感染により細胞の脂質に変化があることを見出すことにより病態解明への手掛かりを得ようという試みられてきたが、前述のヒトレトロウイルス感染によって生じる細胞の糖脂質変化を詳しく調べているうちに、HTLV−I感染細胞において、中性スフィンゴ糖脂質が大きく減少し、一方、アルカリ不安定な糖リン脂質が特徴的にしかも異常に増加していること見出された。また、この細胞へは、HIV、HTLV−Iの病態との関連が注目されているマイクロプラズマ・フェルメンタンス(Mycoplasma fermentans)が感染していることもわかってきた。
【0004】
最近、山本直樹、松田和洋により、前述の感染による発症と密接な関連を有する可能性のある『前記の増加物質の糖リン脂質』が分離、精製されて構造解析が試みられた結果、生理活性を有する可能性のある新規な構造の物質であるホスホリルコリン含有グリセロ糖脂質化合物が見出され、特願平6−21429号として特許出願された。
【0005】
【本発明が解決しようとする問題点】
発明者らは、前記の天然に分離、精製されて構造解析がなされた新規な構造物質であるホスホリルコリン含有グリセロ糖脂質化合物を化学的に合成する方法について鋭意研究を行った結果、この発明の合成法を見出し、発明を完成した。
【0006】
【問題点を解決する手段】
本願における第1の発明は、第1段階において、構造式I
【0007】
【化6】
【0008】
〔但し、構造式Iにおいて、Aは−OH基の保護基であり、R1 及びR2 は炭素数6〜26の炭化水素基である。〕で示される化合物Iとハロゲン化アルキルホスホリルジハライドとを、塩基の存在下、溶媒中で反応させて、構造式II
【0009】
【化7】
【0010】
〔但し、構造式IIにおけるA、R1 及びR2 は前述と同様である。〕で示される化合物IIを合成し、次いで、
第2段階において、前述のようにして得られた化合物IIとトリメチルアミンとを溶媒中で反応させて、構造式III
【0011】
【化8】
【0012】
〔但し、構造式IIIにおけるA、R1 及びR2 は前述と同様である。〕で示される化合物IIIを合成し、最後に、
第3段階において、前述のようにして得られた化合物IIIを水添触媒の存在下に水素と接触させて構造式IV
【0013】
【化9】
【0014】
〔但し、構造式IVにおけるR1 及びR2 は前述と同様である。〕で示される化合物IVを生成することを特徴とするホスホリルコリン含有グリセロ糖脂質化合物の製造法に関する。
また、第2の発明は、構造式III
【0015】
【化10】
【0016】
〔但し、構造式IIIにおいて、A、R1 及びR2 は前述と同様である。〕で示されるホスホリルコリン含有グリセロ糖脂質化合物誘導体に関する。
【0017】
前記の構造式IIIで示される化合物IIIの代表的なものとして、次に示す構造式V(Aがベンジル基である)で示される1,2−ジ−O−パルミトイル−3−O−〔2, 3, 4-トリ−O−ベンジル−6−O−(2−トリメチルアミノエトキシ)−ホスフィナ−ト−α−D−グルコピラノシル〕−sn−グリセロ−ルを挙げることができる。
【0018】
【化11】
【0019】
本発明におけるホスホリルコリン含有グリセロ糖脂質化合物誘導体(即ち、構造式IIIで示される化合物III)は、水添触媒の存在下で水素と接触させることによって、前述のようにして得られた新規な構造物質であるホスホリルコリン含有グリセロ糖脂質化合物〔即ち、前記の構造式IVで示される化合物IVにおいて、R1 及びR2 が−(CH2)14CH3 である化合物を例示できる〕などを容易に得ることができる。
【0020】
前記の各構造式において、保護基Aは、−OH基を、−OA基の状態で保護することができればどのよう種類の保護基であってもよく、例えば、そのような保護基としては、ベンジル基、パラメトキシベンジル基、トリチル基のような置換基を有してもよいアラルキル基が好適である。
【0021】
また、各構造式において、炭素数6〜25の炭化水素基R1 及びR2 は、互いに異なっていても同じであってもよく、そして直鎖状又は分岐状炭化水素基のいずれであってもよく、あるいは炭素−炭素不飽和結合を内部に有している炭化水素であってもよく、例えば、−(CH2)13−CH3 、−(CH2)14−CH3 、−(CH2)15−CH3 などの炭素数10〜20を有する直鎖状アルキル基であることが好ましく、特に−(CH2)14−CH3 が最適である。
【0022】
本発明の製造法は、例えば、次に示す反応式1(1)〜(3)によって示すことができる。なお、反応式1(1)〜(3)における各構造式中のA、R1 及びR2 は、前述に説明したとおりの定義と同じである。
【0023】
【数1】
【0024】
【数2】
【0025】
本発明の製造法における第1段階の反応としては、前記の構造式Iで示される化合物Iとハロゲン化アルキルホスホリルジハライドとを、トリエチルアミン、トリメチルアミン、エチルジイソプロピルアミンのようなトリアルキルアミン等の有機塩基と共に、ハロゲン化炭化水素等の有機溶媒中へ添加して、反応溶液を調製し、その反応溶液を約0〜60℃、特に5〜50℃の反応温度に維持して、約1〜25時間、特に2〜20時間攪拌しながら、化合物Iとハロゲン化アルキルホスホリルジハライドとを反応させて、前記の構造式IIで示される化合物IIを合成することが好ましい。
【0026】
前記のハロゲン化アルキルホスホリルジハライドとしては、例えば、2−ブロモエチルホスホリルジクロライド、2−イオドエチルホスホリルジクロライド、2−クロロエチルホスホリルジクロライドなどを挙げることができる。
前記の第1段階の反応において有機溶媒として使用されるハロゲン化炭化水素としては、トリクロロエチレン、1,2−ジクロルエタン、ジクロルメタンなどを挙げることができる。
【0027】
前記の第1段階の反応において、反応溶液中の化合物Iの濃度は、約1〜50重量%、特に2〜20重量%程度であることが好ましい。
また、前記のトリアルキルアミンの使用割合は、1モルの化合物Iに対して約0.1〜5モル、特に0.2〜2モル程度であることが好ましい。
【0028】
前記の第1段階の反応において、反応が終了した後に反応液から目的物の化合物IIを回収するためには、公知の回収方法を採用することができるが、例えば、反応が終了した後に、反応液を塩酸等の無機酸で酸性として、目的物である化合物IIをエチルエーテル等で抽出して、食塩水等で洗浄した後、無水硫酸マグネシウムで乾燥して、更に、その乾燥された溶液を濃縮しそして精製することによって化合物II(液状物)を得ることが好ましい。
【0029】
本発明の製造法における第2段階において、前述のようにして得られた化合物IIを、トリメチルアミンガスで飽和した有機溶媒に溶解させ、その反応溶液を、約30〜100℃、特に40〜80℃の反応温度に加熱し、その温度で約1〜20時間、特に2〜15時間で化合物IIとトリメチルアミンとを反応させて、さらに、必要であれば、その反応液を冷却した後、反応液へ炭酸銀などの銀塩を臭素陰イオン除去のために加えて、再度、40〜70℃の温度に加熱し、約0.1〜10時間、特に0.2〜5時間還流させて、前記の構造式IIIで示される化合物IIIを合成することが好ましい。
【0030】
前記の第2段階の反応において、反応溶液中の化合物IIの濃度は約1〜50重量%、特に2〜20重量%程度であることが好ましい。
また、前記のトリアルキルアミンの使用割合は、1モルの化合物IIに対して約1.0〜5.0モル、特に3〜4モル程度であることが好ましい。
【0031】
前記の有機溶媒としては、クロロホルム、四塩化炭素、1,2−ジクロロエタン等のハロゲン化炭化水素溶媒、エタノール、プロパノール、ブタノール等の低級脂肪族アルコール、ジメチルホルムアミド(DMF)、ジエチルホルムアミド、ジメチルアセトアミド、ジエチルアセトアミドなどのアミド系溶媒、あるいは、それらの混合溶媒(例えば、クロロホルム−2−プロパノール−DMFの混合溶媒、1,2−ジクロロエタン−2−プロパノール−DMF)が好適である。
【0032】
前記の第2段階の反応において、反応が終了した後に反応液から目的物の化合物IIIを回収するためには、公知の回収方法を採用することができるが、例えば、反応が終了した後に、反応液を室温(約0〜40℃)まで冷却し、セライト等のフィルターを通して濾過し、その濾液を濃縮し、精製して、目的物の化合物III(液状物)を得ることが好ましい。
【0033】
本発明の製造法における第3段階において、前述のようにして得られた化合物IIIを有機溶媒などの溶媒に溶解した溶液にパラジウム系触媒等の水添触媒を添加した混合物を、0〜50℃、特に5〜40℃の温度で、約1〜20時間、特に2〜15時間、水素ガスと接触させて水添反応を行わせることによって化合物IIIの−OA基をすべて−OH基に変換させて、構造式IVで示される化合物IVを生成させることが好ましい。
【0034】
前記の水添触媒としては、水素添加反応に使用できるものであればどのようなものであってもよいが、特に、水酸化パラジウム〔Pd(OH)2 〕、パラジウムブラック、パラジウムカーボン、酢酸パラジウム、シュウ酸パラジウムなどのパラジウム系触媒を好適に挙げることができ、さらに、ニッケル系触媒、白金系触媒も挙げることができる。
その水添触媒の使用割合は、公知の水添反応における使用割合で用いればよいが、特にパラジウム系触媒の場合には、1モルの化合物IIIに対して約0.1〜0.5モル、特に0.3〜0.4モル程度であることが好ましい。
【0035】
前記の第3段階の反応において使用する溶媒としては、メタノール、エタノール、プロパノール、ケトン、メチルエーテル、酢酸、酢酸メチルエステルなどの有機溶媒、水、あるいは、それらの有機溶媒と水との混合液を挙げることができ、特に、メタノール−水−酢酸の混合溶媒(例えば、メタノール:水:酢酸が、10:1:1である混合溶媒)を好適に挙げることができる。
前記の第3段階の反応において、反応が終了した後に反応液から目的物の化合物IVを回収するためには、公知の回収方法を採用することができるが、例えば反応液を濾過し、精製した後、濃縮して、目的物である化合物IV(固体:ワックス状)のを得ることができる。
【0036】
本発明の製造法によって得られる構造式IVで示される化合物IVとしては、次に示す構造式VIで示される化合物VI〔1,2−ジ−O−パルミトイル−3−O−〔6−O−(2−トリメチルアミノエトキシ)−ホスフィナ−ト−α−D−グルコピラノシル〕−sn−グリセロ−ル〕を挙げることができる。
【0037】
【化12】
【0038】
この発明の製造法に使用する構造式Iで示される化合物Iは、反応式2(1)〜(3)、及び、反応式3(1)〜(3)に従って、製造することができる。
反応式2及び3の各構造式において、A、R1 及びR2 は、前述の定義と同様であり、X1 およびX2 は、−OH基の保護基である。
【0039】
【数3】
【0040】
【数4】
【0041】
前述の反応式2で示される反応では、グルコース環の2位、3位及び4位の−OH基が保護基A及び1位及び6位の−OH基がX1 で保護されているα−D−グルコピラノース誘導体(構造式VII:化合物VII)を出発原料として、まず、第1段階(1)で、化合物VIIとハロゲン化水素とを溶媒中で反応させて化合物VIIにおけるグルコース環の1位の−OX1 基のみをBr等のハロゲン原子に変換し構造式VIIIの化合物VIIIを生成し、次いで、第2段階(2)で、(S)−グリシドール(グリシド)と有機塩基化合物と化合物VIIIとを溶媒中で反応させて、化合物VIIIのグルコース環の1位のハロゲン原子を無水グリセロール基に変換して構造式IXの化合物IXを生成し、最後に、第3段階(3)で、その化合物IXとアルカリ金属アルコラートとをアルコール溶媒中で反応させて該化合物IXのグルコース環の6位の−OX1 基のみを−OH基に変換して、1,2-アンヒドロ−3-O−〔α−D−グルコピラノシル〕−Sn−グリセロール誘導体(構造式X:化合物X)を生成することができる。
【0042】
前述の反応式2で示される反応において、出発物質である化合物VIIのグルコース環の1位及び6位に−OX1 基を形成するための水酸基の保護剤としては、p−メトキシベンジルクロライド、p−メトキシベンジルブロマイドなどのベンジルハライド、トリフェニルメチルクロライド、tert−ブチルジメチルシリルクロライド、tert−ブチルジフェニルシリルクロライドなどの『X1 −Hal化合物』を挙げることができる。
【0043】
前述の反応式2で示される第1段階の反応で使用するハロゲン化水素としては塩化水素、臭化水素、ヨウ化水素などを挙げることができるが、特に、臭化水素が好適である。
また、前記の第1段階の反応で使用する溶媒としては、塩化メチレン、トリクロロメタン等のハロゲン化炭化水素溶媒、ジエチルエーテル、ジイソプロピルエーテル等のエーテル系溶媒などを挙げることができる。
【0044】
前述の反応式2で示される第2段階の反応で使用する有機塩基化合物としては、テトラメチル尿素、テトラエチル尿素などの尿素化合物、塩化テトラメチルアンモニウム、臭化テトラメチルアンモニウム、塩化テトラエチルアンモニウム、臭化テトラエチルアンモニウムなどのハロゲン化テトラアルキルアンモニウムなどの窒素系化合物を好適に挙げることができ、特にテトラメチル尿素等の尿素化合物と臭化テトラメチルアンモニウム等のテトラアルキルアンモニウム化合物を併用することが好適である。又、この第2段階の反応で使用する溶媒としては、前述の第1段階の反応で使用する溶媒と同様の溶媒を使用することができる。
【0045】
前述の反応式2における第3段階の反応で使用するアルカリ金属アルコラートとしては、ナトリウムメチラート、ナトリウムエチラートなどを好適に挙げることができ、又、その第3段階の反応で使用するアルコール溶媒としては、メチルアルコール、エチルアルコールなどの低級脂肪族アルコール(炭素数1〜5を有する)を挙げることができる。
【0046】
また、前記の反応式2における反応は、いずれの段階に反応においても反応温度がそれぞれ0〜60℃、特に5〜50℃程度、さらに10〜40℃であることが好ましく、一方、前記反応式2の反応における反応時間が、第1段階では1〜60分間、特に5〜50分間、また、第2段階では1〜60分間、特に2〜30分間、さらに、第2段階では、1〜50時間、特に2〜40時間程度であることが好ましい。
【0047】
反応式3で示される反応では、前述の反応式2(1)〜(3)の反応で得られた『グルコース環の2位、3位及び4位が保護基Aで保護されている1,2-アンヒドロ−3-O−〔α−D−グルコピラノシル〕−Sn−グリセロール誘導体(構造式X:化合物X)』を出発原料として、まず、第1段階(1)で、化合物Xと、高級カルボン酸金属塩(R1 −COOM)との混合物を溶媒中で高温で反応反応させ、化合物Xのグリシジル基のエポキシ環を開環させて、ハーフエステル構造を有する構造式XIで示される化合物XIを生成さる。
【0048】
次いで、反応式3の第2段階(2)で、化合物XIと、トリアルキルアミン、アルキルアミノピリジン等の有機塩基とを溶解した塩化メチレン等の溶媒の溶液に、水酸基の保護剤(X2 −Hal)および高級カルボン酸ハライド(R2 −CO−Hal)の塩化メチレン等の溶媒の溶液を添加して、その結果、化合物XIと保護剤(X2 −Hal)と高級カルボン酸ハライド(R2 −CO−Hal)とを反応させて、化合物XIのグルコース環の6位の−OH基を−OX2 基に変換すると共に該化合物XIのグリセロール構造の2位の−OH基をエステル結合に変換させて構造式XIIで示される化合物XIIを生成させる。
【0049】
最後に、反応式3の第3段階(3)で、前記の化合物XIIをトリフルオロ酢酸のアルコール溶液に添加して、0〜50℃、特に5〜40℃、さらに室温付近で約1〜20時間、特に2〜15時間、十分に反応させて、前記の化合物XIIのグルコース環の6位の−OX2 基を再度−OH基に変換させて、本発明の製造法に出発物質として使用される『構造式Iで示される化合物I』を生成させるのである。
【0050】
前記の反応式3の第1段階(1)で使用される高級カルボン酸金属塩(R1 −COOM)としては、ラウリン酸、トリデシル酸、ミスチン酸、ペンタデシル酸、パルミチン酸、ヘプタデシル酸、ステアリン酸等の高級脂肪族カルボン酸と、炭酸セシウム、炭酸ナトリウム、炭酸マグネシウム、炭酸カリウム等の炭酸金属塩とから得られた炭素数10〜20を有する高級脂肪族カルボン酸金属塩(例えば、パルミチン酸セシウム)を好適に挙げることができる。
【0051】
前記反応式3の第1段階(1)においては、反応温度が80〜200℃、特に100〜150℃程度であり、また、反応時間が1〜20時間、特に2〜15時間程度であることが好ましく、さらに、反応溶媒として、ジメチルホルムアミド(DMF)、ヘキサメチルホスホニウムアミド、エチレングリコールを挙げることができる。
【0052】
前記反応式3の第2段階(2)で使用される水酸基の保護剤(X2 −Hal)としては、tert−ブチルジメチルシリルクロライド、tert−ブチルジフェニルシリルクロライドなどのトリアルキルシリルハライドが好ましい。
また、前記反応式3の第2段階(2)で使用される高級カルボン酸ハライドとしては、ラウリン酸クロライド、トリデシル酸クロライド、ミスチン酸クロライド、ペンタデシル酸クロライド、パルミチン酸クロライド、ヘプタデシル酸クロライド、ステアリン酸クロライドなどの炭素数10〜20を有するカルボン酸ハライドを好適に挙げることができる。
【0053】
前記の反応式2及び3の反応において、反応中間体又は目的物である各化合物のグルコース環の2位、3位及び4位の−OA基は、いずれも−OH基に変換されることなく各反応が行われることが好ましく、前記の−OA基が各反応条件に対してかなり安定であることが好ましい。
【0054】
以下、本発明の製造法に関する実施例、及び参考例を示す。
前記の実施例及び参考例において、得られた反応生成物の融点は未補正のまま使用し、IRスペクトルはJASCO A−202分光計で測定し、 1H−NMRスペクトルはJEOL GX−400または270 MHzの分光計を用い、溶媒としてCDCl3 (重水素化クロロホルム)を用い、また内部標準(物質)としてTMS(テトラメチルシラン)を用いて測定し、さらに、旋光度は、波長586nmでJASCO J−20で測定した〔K8sel gel 60 F254 (メルク社製)をTLC分析に用いた。〕
【0055】
前記の実施例及び参考例において、濃縮は減圧下に揮発分の蒸発によって行い、濾過はセライトを通して行った。
さらに、実施例及び参考例において、反応液の後処理は、塩化メチレンで希釈し、水で洗浄し、飽和炭酸水素ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥し、濾過し、濃縮することによって行った。
【0056】
参考例1
〔反応式2−(1)の反応〕
2,3,4−トリ−O−ベンジル−6−O−p−ニトロベンゾイル−α−D−グルコピラノシルブロミド(化合物VIII)の合成
2,3,4−トリ−O−ベンジル−1,6−ジ−O−p−ニトロベンゾイル−D−グルコピラノ−ス(1.45g、1.94mmol)の臭化水素で飽和した塩化メチレン液(15ml)を室温中で、30分間攪拌した。セライトを通して濾過した後、溶液を減圧下濃縮し、塩化メチレン(5ml)を加えて減圧下濃縮を繰り返して、得られた化合物VIII1,2)のシロップ状の残渣を、更なる精製をすることなく次の参考例2の反応〔反応式2−(2)〕に供した。
【0057】
1)T.Ishikawa and H.G.Fletcher,J.Am.Chem.Soc.,34,563(1969).
2)R.U.Lemieux, K.B.Hendrix, R.V.Stick and k.James,J.Am.Chem.Soc.,97,4056(1975).
【0058】
〔反応式2−(2)の反応〕
1,2−アンヒドロ−3−O−〔2,3,4−トリ−O−ベンジル−6−O−p−ニトロベンゾイル−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物IX)の合成
塩化メチレン中の(S)−グリシド−ル(グリシド)(720mg,9.7mmol)、テトラメチル尿素(338mg、2.9mmol)、臭化テトラエチルアンモニウム(440mg,3.8mg)および粉状モリキュラ−シ−ブ3A(300mg)の混合物の塩化メチレン溶液(10ml)を室温で15分間攪拌した。上記参考例1のようにして合成した1.45gの2,3,4−トリ−O−ベンジル−1, 6−O−p−ニトロベンゾイル−α−D−グルコピラノシルブロマイド(化合物VII1)の塩化メチレン溶液5mlを室温下5分間で該混合物の塩化メチレン溶液に添加し、反応混合物を一夜攪拌した。混合液は通常の後処理を行い、そして得られたシロップはシリカゲルカラムクロマトグラフィ−(溶媒;トルエン:酢酸エチル=10:1)で精製して、シロップ状の化合物IXを972mg(収率:78%)得た。
1H−NMR(ppm) :4.96(1H, d, J=3.8Hz, H-1') 、2.60(1H, dd, J=2.8, 4.9Hz, H-1a) 、2.79(1H, dd, J=4.3, 4.9Hz, H-1b)、3.22(1H, m, H-2)、3.83(1H, dd, J=3.0, 12.0Hz, H-3a )、3.50(1H, dd, J=6.3, 12.0Hz, H-3b )
【0059】
〔反応式2−(3)の反応〕
1,2−アンヒドロ−3−O−〔2,3,4−トリ−O−ベンジル−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物X)の合成
参考例2で得られた化合物IXの粗製シロップ(500mg)とナトリウムメチラ−ト10mgを含むメタノ−ル溶液(10ml)との混合物を3時間攪拌し、Amberlyst 15(H +型)で中和処理し、そしてシロップ状の化合物Xを384mg(収率:100%)得た。
〔α〕22 D :+38°(CHCl3 ,c 0.1)、
1H−NMR(ppm) :4.90(1H, d, J=3.6Hz, H-1') 、2.60(1H, dd, J=4.6, 4.8Hz, H-1a) 、2.80(1H, dd, J=4.5, 4.5Hz, H-1b)、3.21(1H, m, H-2)、3.83(1H, dd, J=3.1, 11.8Hz, H-3a )、3.50(1H, dd, J=6.3, 11.8Hz, H-3b )
【0060】
参考例2
〔反応式3−(1)の反応〕
1−O−パルミトイル−3−O−〔2,3,4−トリ−O−ベンジル−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物XI)の合成
DMF(10ml)中の化合物X(300mg、0.61mmol)、パルミチン酸(1g)および炭酸セシウム(650mg)との混合物を、8時間、120〜130℃で攪拌した。混合物を濾過しそして通常の後処理を行い、化合物XIをワックス状の固体として390mg(収率:85%)得た。
〔α〕22 D :+25°(CHCl3 ,c 0.2)、mp.:38℃、
1H−NMR:4.74(1H, d, J=3.5Hz, H-1)、3.40(1H, dd, J=7.5, 10.2Hz, H-1a)、3.77(1H, H-1b)、4.05(1H, m, H-2)、4.14(1H, dd, J=5.6, 11.7Hz, H-3a )、4.18(1H, dd, J=4.5, 11.7Hz, H-3b )、FB−MS:704(M+1)
【0061】
〔反応式3−(2)の反応〕
1,2−ジ−O−パルミトイル−3−O−〔2,3,4−トリ−O−ベンジル−6−O−tert−ブチルジメチルシリル−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物XII)の合成
化合物XI(200mg,0.26mmol)、トリエチルアミン(0.2ml)及びN,N−ジメチルアミノピリジン(100mg)の塩化メチレン溶液10mlに攪拌下、tert−ブチルジメチルシリルクロライド(50mg、0.33mmol)の塩化メチレン溶液0.5mlを添加した。室温で12時間攪拌後、塩化パルミトイル(150mg,0.55mmol)を添加し、さらに6時間攪拌した。混合物に水0.2mlを加え、そして30分間攪拌した。有機層を分離し、通常の後処理を行った。シリカゲルカラムクロマトグラフィ−(溶媒;n−ヘキサン:酢酸エチル=50:1)で精製して、シロップ状の化合物XIIを252mg(収率:86%)得た。
1H−NMR(CDCl3 、ppm ):4.75(1H, d, J=3.6Hz, H-1) 、3.53(1H, dd, J =6.1, 11.2Hz, H-3a)、3.74(1H, dd, J=5.3, 11.2Hz, H-3b )、5.24(1H, m, H-2)、4.40(1H, dd, J=3.5, 11.9Hz, H-1a )、4.20(1H, dd, J=5.8, 11.9Hz, H-1b )、FB−MS:878(M+1)
【0062】
〔反応式3−(3)の反応〕
1,2−ジ−O−パルミトイル−3−O−〔2,3,4−トリ−O−ベンジル−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物I)
化合物XII(200mg、0.18mmol)とトリフルオロ酢酸(0.1ml)との混合物のメタノ−ル溶液(0.9ml)を、室温で、12時間攪拌した。そして、その後減圧濃縮し、トルエンを加えて減圧下に繰り返し濃縮した。残渣はシリカゲルカラムクロマトグラフィ−(溶媒;トルエン:酢酸エチル=5:1)で精製して、ワックス状の固体として化合物Iを170mg(収率:95%)得た。
〔α〕22 D :+23°(c 0.2,CHCl3 )、 1H−NMR(ppm) :4.71(1H, d, J=3.6Hz, H-1) 、4.42(1H, dd, J=3.7, 12.0Hz, H-1a)、4.19(1H, dd, J =6.2, 12.0Hz, H-1b)、3.96(1H, t, J=9.2Hz, H-3')、0.88(6H, t, J=7Hz, CH3)、5.24(1H, m, H-2)、3.55(1H, dd, J=5.1, 10.8Hz, H-3a)、3.74(1H, dd, J=6.0, 10.8Hz, H-3b)、FB−MS:1002(M+1)
【0063】
実施例1
〔反応式1−(1)の反応〕
1,2−ジ−O−パルミトイル−3−O−〔2,3,4−トリ−O−ベンジル−6−O−(2−ブロモエトキシ)−フォスフィナ−ト−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物II)の合成
トリエチルアミン(0.12ml)と2−ブロモエチル−ホスホリル−ジクロライド(100mg)とのトリクロロエチレン溶液2mlを化合物I(150mg、0.15mmol)のトリクロルエチレン溶液(3.2ml)に添加した。そして混合物は室温下で12時間攪拌した。エチルエ−テル(5ml)とトリエチルアミン(0.1ml)を添加した後、混合物を2時間還流した。冷却後、反応混合物は5%塩酸で酸性とし、エチルエ−テルで抽出し、飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥した。溶液を濃縮し、シリカゲルカラムクロマトグラフィ−(溶媒;クロロホルム:メタノ−ル=10:1)で精製して、シロップ状の化合物IIを141mg(収率:79%)得た。
〔α〕22 D :+11.4°(c 0.35,CHCl3 )、 1H−NMR(ppm) :0.88(6H, t, CH3) 、4.72(1H, d, J=3.7Hz, H-1')、4.40(1H, dd, J=3.3, 12.1Hz, H-1a)、4.19(1H, dd, J=6.1, 12.1Hz, H-1b)、5.23(1H, m, H-2) 、3.95(1H, t, J=9.3Hz, H-3')、4.10(2H, m, -CH2-O-P)、3.42(2H, t,-CH2-Br)、FB−MS:1188(M+1)
【0064】
〔反応式1−(2)の反応〕
1,2−ジ−O−パルミトイル−3−O−〔2, 3, 4-トリ−O−ベンジル−6−O−(2−トリメチルアミノエトキシ)−ホスフィナ−ト−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物III)の合成
トリメチルアミン(ガス)で飽和しているクロロホルム−2−プロパノ−ル−DMF(3:5:5)混合溶液3mlに化合物II(100mg、0.08mmol)を溶解した後、70℃で8時間加熱し、その後冷却し、炭酸銀を加えた。反応混合液は加熱下(70℃)で1時間還流し、その後室温まで冷却した。そしてセライトを通して濾過した。濾液を濃縮し、残渣はシリカゲルカラムクロマトグラフィ−(溶媒;クロロホルム:メタノ−ル=1:1)で精製して、シロップ状の化合物IIIを61mg(収率:62%)得た。
〔α〕22 D :+30.0°(c 0.04,CHCl3)、 1H−NMR(ppm) :0.88(6H, t, CH3) 、3.17(9H, S, N(CH3)3)、3.92(1H, t, J =9.3Hz, H-3')、4.18(1H, dd, J=6.0, 12.1Hz, H-1b)、4.39(1H, dd, J=3.3, 12.1Hz, H-1a)、5.23(1H, m, H-2)、FB−MS:1175(M+1)
【0065】
〔反応式1−(3)の反応〕
1,2−ジ−O−パルミトイル−3−O−〔6−O−(2−トリメチルアミノエトキシ)−ホスフィナ−ト−α−D−グルコピラノシル〕−sn−グリセロ−ル(化合物IV)(GGPL−I)の合成
化合物III(50mg,0.04mmol)および水酸化パラジウム〔Pd(OH)2 〕(50mg)の混合物を室温で12時間水素ガスと処理した(メタノール:水:酢酸=10:1:1である混合溶媒、5ml)。その反応液を濾過し、溶媒を濃縮してワックス状の固体として化合物IV(GGPL−I)を35mg(収率:91%)得た。
〔α〕22 D :24.9゜(c 0.06,CHCl3 :MeOH=2:1)、
FB−MS 897(M+1)
1H−NMR(DMSO−d6 ): 3.13(9H, S, N(CH3)3) 、3.53(1H, dd, J =5.4, 11.0Hz, H-3a )、3.68(1H, dd, J=5.2, 11.0Hz, H-3b )、4.32
(1H, dd, J=3.2, 11.8Hz, H-1a)、4.14(1H, dd, J=6.7, 11.8Hz, H-1b)、4.65(1H, d, J=3.6Hz, H-1' )
【0066】
【本発明の作用効果】
本発明の製造法は、水酸基が保護されているグリセロ糖脂質化合物誘導体を出発原料として天然にしか得られなかったホスホリルコリン含有グリセロ糖脂質化合物を化学的に製造することができる新規な製造法を提供するものである。
また、本発明は、その中間体である1,2−ジ−O−パルミトイル−3−O−〔2, 3, 4-トリ−O−ベンジル−6−O−(2−トリメチルアミノエトキシ)−ホスフィナ−ト−α−D−グルコピラノシル〕−sn−グリセロ−ルを含む新規な化合物に関する。[0001]
[Industrial application fields]
The present invention relates to a novel “phosphorylcholine-containing α-glucose found from the lipid fraction of human helper T cells co-infected with Mycoplasma fermentans-HTLV-I (Human T-lymphotropic virus type I). The present invention provides a method for chemically synthesizing a (sugar) lipid compound, and a novel intermediate compound in the synthesis method.
[0002]
[Description of Related Art]
Conventionally, it has been known that virus infection causes a large change in the glycolipid sugar chain of cells. Human retroviruses HTLV-I and HIV (human immunodeficiency virus) are both particularly susceptible to infecting helper T cells among lymphocytes. HTLV-I transforms this into a monoclonal tumor and HIV destroys it. To develop.
[0003]
Attempts have been made to obtain clues to elucidate the pathophysiology by finding that there are changes in the lipids of cells due to these viral infections, but we are investigating changes in glycolipids in cells caused by the aforementioned human retrovirus infection In the meantime, it has been found that neutral glycosphingolipids are greatly decreased in HTLV-I-infected cells, while alkali-labile glycophospholipids are characteristically and abnormally increased. It has also been found that these cells are infected with microplasma fermentans (Mycoplasma fermentans), which is attracting attention for its relationship with the pathological conditions of HIV and HTLV-I.
[0004]
Recently, Naoki Yamamoto and Kazuhiro Matsuda have isolated and purified the “increased glycophospholipids,” which may be closely related to the onset of the infection described above. A phosphorylcholine-containing glyceroglycolipid compound, which is a substance having a novel structure that may have the above-mentioned, was discovered, and a patent application was filed as Japanese Patent Application No. 6-21429.
[0005]
[Problems to be solved by the present invention]
The inventors have conducted extensive research on a method for chemically synthesizing phosphorylcholine-containing glyceroglycolipid compounds, which are novel structural substances that have been naturally separated, purified and structurally analyzed. We found the law and completed the invention.
[0006]
[Means for solving problems]
According to a first aspect of the present invention, in the first stage, the structural formula I
[0007]
[Chemical 6]
[0008]
[In the structural formula I, A is a protecting group for —OH group;1And R2Is a hydrocarbon group having 6 to 26 carbon atoms. And a halogenated alkylphosphoryl dihalide in the presence of a base in a solvent to give a structural formula II
[0009]
[Chemical 7]
[0010]
[However, A, R in Structural Formula II1And R2Is the same as described above. And then compound II,
In the second stage, the compound II obtained as described above and trimethylamine are reacted in a solvent to give the structural formula III
[0011]
[Chemical 8]
[0012]
[However, A, R in Structural Formula III1And R2Is the same as described above. And finally compound III,
In the third stage, the compound III obtained as described above is contacted with hydrogen in the presence of a hydrogenation catalyst to give the structural formula IV
[0013]
[Chemical 9]
[0014]
[However, R in Structural Formula IV1And R2Is the same as described above. ] The manufacturing method of the phosphorylcholine containing glyceroglycolipid compound characterized by producing | generating compound IV shown by this.
The second invention is the structural formula III
[0015]
[Chemical Formula 10]
[0016]
[However, in Structural Formula III, A, R1And R2Is the same as described above. ] The phosphorylcholine containing glyceroglycolipid compound derivative shown by these.
[0017]
As a typical compound III represented by the above structural formula III, 1,2-di-O-palmitoyl-3-O- [2 represented by the following structural formula V (A is a benzyl group) , 3, 4-tri-O-benzyl-6-O- (2-trimethylaminoethoxy) -phosphinate- [alpha] -D-glucopyranosyl] -sn-glycerol.
[0018]
Embedded image
[0019]
The phosphorylcholine-containing glyceroglycolipid compound derivative (that is, the compound III represented by the structural formula III) in the present invention is a novel structural substance obtained as described above by contacting with hydrogen in the presence of a hydrogenation catalyst. A phosphorylcholine-containing glyceroglycolipid compound [that is, in the compound IV represented by the above structural formula IV, R1And R2Is-(CH2)14CHThreeCan be easily obtained.
[0020]
In each of the structural formulas described above, the protecting group A may be any kind of protecting group as long as it can protect the —OH group in the state of —OA group. Aralkyl groups which may have a substituent such as benzyl group, paramethoxybenzyl group and trityl group are preferred.
[0021]
In each structural formula, a hydrocarbon group R having 6 to 25 carbon atoms.1And R2May be the same or different from each other, and may be either a linear or branched hydrocarbon group, or a hydrocarbon having a carbon-carbon unsaturated bond therein. For example,-(CH2)13-CHThree,-(CH2)14-CHThree,-(CH2)15-CHThreeIt is preferably a linear alkyl group having 10 to 20 carbon atoms such as-(CH2)14-CHThreeIs the best.
[0022]
The production method of the present invention can be represented by, for example, the following reaction formulas 1 (1) to (3). In addition, A and R in each structural formula in Reaction Formula 1 (1) to (3)1And R2Is the same definition as described above.
[0023]
[Expression 1]
[0024]
[Expression 2]
[0025]
In the first stage reaction in the production method of the present invention, the compound I represented by the structural formula I and the halogenated alkylphosphoryl dihalide are mixed with an organic compound such as trialkylamine such as triethylamine, trimethylamine or ethyldiisopropylamine. A base solution is added to an organic solvent such as a halogenated hydrocarbon to prepare a reaction solution, and the reaction solution is maintained at a reaction temperature of about 0 to 60 ° C., particularly 5 to 50 ° C. It is preferred to synthesize compound II represented by the above structural formula II by reacting compound I with a halogenated alkylphosphoryl dihalide with stirring for 2 to 20 hours.
[0026]
Examples of the halogenated alkyl phosphoryl dihalide include 2-bromoethyl phosphoryl dichloride, 2-iodoethyl phosphoryl dichloride, 2-chloroethyl phosphoryl dichloride, and the like.
Examples of the halogenated hydrocarbon used as the organic solvent in the first stage reaction include trichloroethylene, 1,2-dichloroethane, dichloromethane and the like.
[0027]
In the first stage reaction, the concentration of Compound I in the reaction solution is preferably about 1 to 50% by weight, particularly about 2 to 20% by weight.
Moreover, it is preferable that the usage-amount of the said trialkylamine is about 0.1-5 mol with respect to 1 mol of compound I, especially about 0.2-2 mol.
[0028]
In the first stage reaction, a known recovery method can be employed to recover the target compound II from the reaction solution after the reaction is completed. For example, after the reaction is completed, The solution is acidified with an inorganic acid such as hydrochloric acid, and the target compound II is extracted with ethyl ether or the like, washed with brine, dried over anhydrous magnesium sulfate, and the dried solution is further purified. It is preferred to obtain compound II (liquid) by concentrating and purifying.
[0029]
In the second step of the production method of the present invention, the compound II obtained as described above is dissolved in an organic solvent saturated with trimethylamine gas, and the reaction solution is about 30-100 ° C., particularly 40-80 ° C. The compound II is reacted with trimethylamine for about 1 to 20 hours, particularly 2 to 15 hours at that temperature, and further, if necessary, the reaction solution is cooled to the reaction solution. A silver salt such as silver carbonate is added to remove the bromine anion, heated again to a temperature of 40 to 70 ° C., and refluxed for about 0.1 to 10 hours, particularly 0.2 to 5 hours. It is preferred to synthesize compound III represented by structural formula III.
[0030]
In the second stage reaction, the concentration of Compound II in the reaction solution is preferably about 1 to 50% by weight, particularly about 2 to 20% by weight.
Moreover, it is preferable that the usage-amount of the said trialkylamine is about 1.0-5.0 mol with respect to 1 mol of compound II, especially about 3-4 mol.
[0031]
Examples of the organic solvent include halogenated hydrocarbon solvents such as chloroform, carbon tetrachloride and 1,2-dichloroethane, lower aliphatic alcohols such as ethanol, propanol and butanol, dimethylformamide (DMF), diethylformamide, dimethylacetamide, An amide solvent such as diethylacetamide or a mixed solvent thereof (for example, a mixed solvent of chloroform-2-propanol-DMF, 1,2-dichloroethane-2-propanol-DMF) is preferable.
[0032]
In the second stage reaction, a known recovery method can be employed to recover the target compound III from the reaction solution after the reaction is completed. For example, after the reaction is completed, The solution is cooled to room temperature (about 0 to 40 ° C.), filtered through a filter such as Celite, and the filtrate is concentrated and purified to obtain the desired compound III (liquid).
[0033]
In the third step of the production method of the present invention, a mixture obtained by adding a hydrogenation catalyst such as a palladium-based catalyst to a solution obtained by dissolving the compound III obtained as described above in a solvent such as an organic solvent, In particular, the hydrogenation reaction is carried out by contacting with hydrogen gas at a temperature of 5 to 40 ° C. for about 1 to 20 hours, particularly 2 to 15 hours, thereby converting all —OA groups of compound III into —OH groups. Thus, it is preferable to produce the compound IV represented by the structural formula IV.
[0034]
The hydrogenation catalyst may be any one as long as it can be used for the hydrogenation reaction. In particular, palladium hydroxide [Pd (OH)2Palladium catalysts such as palladium black, palladium carbon, palladium acetate and palladium oxalate can be preferably mentioned, and nickel catalysts and platinum catalysts can also be mentioned.
The hydrogenation catalyst may be used in a known hydrogenation reaction, particularly in the case of a palladium-based catalyst, about 0.1 to 0.5 mol with respect to 1 mol of compound III, In particular, the amount is preferably about 0.3 to 0.4 mol.
[0035]
As the solvent used in the third stage reaction, an organic solvent such as methanol, ethanol, propanol, ketone, methyl ether, acetic acid, and acetic acid methyl ester, water, or a mixture of these organic solvents and water is used. In particular, a mixed solvent of methanol-water-acetic acid (for example, a mixed solvent in which methanol: water: acetic acid is 10: 1: 1) can be preferably exemplified.
In the third stage reaction, a known recovery method can be employed to recover the target compound IV from the reaction solution after the reaction is completed. For example, the reaction solution is filtered and purified. Thereafter, the compound IV (solid: waxy) as the target product can be obtained by concentration.
[0036]
Compound IV represented by Structural Formula IV obtained by the production method of the present invention includes Compound VI [1,2-di-O-palmitoyl-3-O- [6-O— represented by Structural Formula VI shown below. (2-trimethylaminoethoxy) -phosphinate-α-D-glucopyranosyl] -sn-glycerol].
[0037]
Embedded image
[0038]
The compound I represented by the structural formula I used in the production method of the present invention can be produced according to the reaction formulas 2 (1) to (3) and the reaction formulas 3 (1) to (3).
In each structural formula of reaction formulas 2 and 3, A, R1And R2Is as defined above, X1And X2Is a protecting group for —OH group.
[0039]
[Equation 3]
[0040]
[Expression 4]
[0041]
In the reaction represented by the aforementioned reaction formula 2, the —OH groups at the 2-position, 3-position and 4-position of the glucose ring are the protecting group A and the —OH groups at the 1-position and the 6-position are X1First, in the first step (1), compound VII and hydrogen halide are reacted in a solvent using α-D-glucopyranose derivative (Structural Formula VII: Compound VII) protected with -OX at position 1 of the glucose ring in VII1Only the group is converted to a halogen atom such as Br to produce compound VIII of structural formula VIII, and then in the second stage (2), (S) -glycidol (glycid), organic base compound and compound VIII are dissolved in a solvent. To form a compound IX of the structural formula IX by converting the halogen atom at the 1-position of the glucose ring of the compound VIII to an anhydrous glycerol group. Finally, in the third step (3), the compound IX and an alkali A metal alcoholate is reacted in an alcohol solvent to form -OX at the 6-position of the glucose ring of the compound IX.1Only the group can be converted to an —OH group to produce a 1,2-anhydro-3-O- [α-D-glucopyranosyl] -Sn-glycerol derivative (Structural Formula X: Compound X).
[0042]
In the reaction represented by the above-mentioned reaction formula 2, -OX at positions 1 and 6 of the glucose ring of the starting compound, compound VII1Examples of the hydroxyl group-protecting agent for forming a group include benzyl halides such as p-methoxybenzyl chloride and p-methoxybenzyl bromide, triphenylmethyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride and the like. X1-Hal compound ".
[0043]
Examples of the hydrogen halide used in the first-stage reaction represented by the above-described reaction formula 2 include hydrogen chloride, hydrogen bromide, hydrogen iodide, and the like, and hydrogen bromide is particularly preferable.
Examples of the solvent used in the first stage reaction include halogenated hydrocarbon solvents such as methylene chloride and trichloromethane, and ether solvents such as diethyl ether and diisopropyl ether.
[0044]
Examples of the organic base compound used in the second stage reaction shown in the above reaction formula 2 include urea compounds such as tetramethylurea and tetraethylurea, tetramethylammonium chloride, tetramethylammonium bromide, tetraethylammonium chloride, bromide. Nitrogen compounds such as tetraalkylammonium halides such as tetraethylammonium can be preferably mentioned, and it is particularly preferable to use a urea compound such as tetramethylurea and a tetraalkylammonium compound such as tetramethylammonium bromide in combination. . As the solvent used in the second stage reaction, a solvent similar to the solvent used in the first stage reaction described above can be used.
[0045]
As the alkali metal alcoholate used in the third stage reaction in the above-mentioned reaction formula 2, sodium methylate, sodium ethylate and the like can be preferably mentioned, and as the alcohol solvent used in the third stage reaction, Can include lower aliphatic alcohols (having 1 to 5 carbon atoms) such as methyl alcohol and ethyl alcohol.
[0046]
Further, the reaction in the reaction formula 2 is preferably performed at a reaction temperature of 0 to 60 ° C., particularly about 5 to 50 ° C., and more preferably 10 to 40 ° C. in any stage. The reaction time in the reaction of 2 is 1 to 60 minutes, particularly 5 to 50 minutes in the first stage, 1 to 60 minutes, particularly 2 to 30 minutes in the second stage, and 1 to 50 in the second stage. It is preferable that the time is about 2 to 40 hours.
[0047]
In the reaction represented by the reaction formula 3, “the 2-position, 3-position and 4-position of the glucose ring are protected with a protective group A obtained by the reaction of the above-mentioned reaction formulas 2 (1) to (3) 1, Using 2-anhydro-3-O- [α-D-glucopyranosyl] -Sn-glycerol derivative (Structural Formula X: Compound X) ”as a starting material, first, in the first step (1), compound X and higher carboxyl Acid metal salt (R1-COOM) is reacted at elevated temperature in a solvent to open the epoxy ring of the glycidyl group of Compound X to produce Compound XI, which is represented by Structural Formula XI having a half ester structure.
[0048]
Next, in the second step (2) of Reaction Scheme 3, a hydroxyl protecting agent (X) is added to a solution of a solvent such as methylene chloride in which Compound XI and an organic base such as trialkylamine or alkylaminopyridine are dissolved.2-Hal) and higher carboxylic acid halides (R)2-CO-Hal) in a solvent such as methylene chloride was added, resulting in compound XI and protecting agent (X2-Hal) and higher carboxylic acid halides (R)2-CO-Hal) is reacted with -OH group at the 6-position of the glucose ring of compound XI to -OX2And the —OH group at the 2-position of the glycerol structure of Compound XI is converted to an ester bond to produce Compound XII represented by Structural Formula XII.
[0049]
Finally, in the third step (3) of the reaction scheme 3, the compound XII is added to an alcohol solution of trifluoroacetic acid, and 0 to 50 ° C., particularly 5 to 40 ° C. and about 1 to 20 at room temperature. -OX for the 6-position of the glucose ring of the compound XII after sufficient reaction for a period of time, in particular 2 to 15 hours2The group is converted again to the —OH group to produce “Compound I represented by Structural Formula I” used as a starting material in the production method of the present invention.
[0050]
The higher carboxylic acid metal salt (R) used in the first step (1) of Reaction Scheme 3 above1-COOM) includes higher aliphatic carboxylic acids such as lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, heptadecylic acid, stearic acid, and metal carbonates such as cesium carbonate, sodium carbonate, magnesium carbonate, and potassium carbonate. A higher aliphatic carboxylic acid metal salt (for example, cesium palmitate) having 10 to 20 carbon atoms obtained from the salt can be preferably mentioned.
[0051]
In the first step (1) of the reaction formula 3, the reaction temperature is 80 to 200 ° C., particularly about 100 to 150 ° C., and the reaction time is 1 to 20 hours, particularly about 2 to 15 hours. Furthermore, examples of the reaction solvent include dimethylformamide (DMF), hexamethylphosphonium amide, and ethylene glycol.
[0052]
Hydroxyl protective agent (X) used in the second step (2) of the reaction formula 32-Hal) is preferably a trialkylsilyl halide such as tert-butyldimethylsilyl chloride or tert-butyldiphenylsilyl chloride.
The higher carboxylic acid halide used in the second step (2) of the reaction formula 3 includes lauric acid chloride, tridecyl acid chloride, myristic acid chloride, pentadecylic acid chloride, palmitic acid chloride, heptadecyl acid chloride, stearic acid. Preferable examples include carboxylic acid halides having 10 to 20 carbon atoms such as chloride.
[0053]
In the reactions of the above reaction formulas 2 and 3, -OA groups at the 2-position, 3-position and 4-position of the glucose ring of each compound which is a reaction intermediate or target product are not converted to -OH groups. Each reaction is preferably carried out, and it is preferred that the -OA group is fairly stable to each reaction condition.
[0054]
Hereinafter, the Example regarding the manufacturing method of this invention and a reference example are shown.
In the above examples and reference examples, the melting point of the obtained reaction product was used without correction, and the IR spectrum was measured with a JASCO A-202 spectrometer.1The H-NMR spectrum was measured using a JEOL GX-400 or 270 MHz spectrometer with CDCl as the solvent.Three(Deuterated chloroform) was used, and TMS (tetramethylsilane) was used as an internal standard (substance), and the optical rotation was measured with JASCO J-20 at a wavelength of 586 nm [K8sel gel 60 F254(Merck) was used for TLC analysis. ]
[0055]
In the above Examples and Reference Examples, concentration was performed by evaporation of volatiles under reduced pressure, and filtration was performed through Celite.
Furthermore, in the examples and reference examples, the reaction solution was worked up by diluting with methylene chloride, washing with water, washing with a saturated aqueous sodium bicarbonate solution, drying over anhydrous magnesium sulfate, filtration, and concentration. went.
[0056]
Reference example 1
[Reaction of Reaction Formula 2- (1)]
Synthesis of 2,3,4-tri-O-benzyl-6-Op-nitrobenzoyl-α-D-glucopyranosyl bromide (Compound VIII)
2,3,4-Tri-O-benzyl-1,6-di-Op-nitrobenzoyl-D-glucopyranose (1.45 g, 1.94 mmol) in methylene chloride saturated with hydrogen bromide ( 15 ml) was stirred at room temperature for 30 minutes. After filtration through celite, the solution was concentrated under reduced pressure, methylene chloride (5 ml) was added, and concentration was repeated under reduced pressure to obtain the obtained compound VIII.1,2)The syrup-like residue was subjected to the reaction of the following Reference Example 2 [Reaction Formula 2- (2)] without further purification.
[0057]
1) T. Ishikawa and H. G. Fletcher, J. Am. Chem. Soc., 34, 563 (1969).
2) R.U.Lemieux, K.B.Hendrix, R.V.Stick and k.James, J.Am.Chem.Soc., 97, 4056 (1975).
[0058]
[Reaction of Reaction Formula 2- (2)]
Synthesis of 1,2-anhydro-3-O- [2,3,4-tri-O-benzyl-6-Op-nitrobenzoyl-α-D-glucopyranosyl] -sn-glycerol (Compound IX)
(S) -Glycidol (glycid) (720 mg, 9.7 mmol), tetramethylurea (338 mg, 2.9 mmol), tetraethylammonium bromide (440 mg, 3.8 mg) and powdered molecular formula in methylene chloride. A mixture of 3A (300 mg) in methylene chloride (10 ml) was stirred at room temperature for 15 minutes. 1.45 g of 2,3,4-tri-O-benzyl-1,6-Op-nitrobenzoyl-α-D-glucopyranosyl bromide (Compound VII1) synthesized as in Reference Example 1 above Of methylene chloride was added to the mixture in methylene chloride at room temperature for 5 minutes and the reaction mixture was stirred overnight. The mixture was subjected to usual work-up, and the resulting syrup was purified by silica gel column chromatography (solvent; toluene: ethyl acetate = 10: 1) to give 972 mg of syrupy compound IX (yield: 78% )Obtained.
1H-NMR (ppm): 4.96 (1H, d, J = 3.8 Hz, H-1 ′), 2.60 (1H, dd, J = 2.8, 4.9 Hz, H-1a), 2.79 (1H, dd, J = 4.3, 4.9Hz, H-1b), 3.22 (1H, m, H-2), 3.83 (1H, dd, J = 3.0, 12.0Hz, H-3a), 3.50 (1H, dd, J = 6.3, 12.0) Hz, H-3b)
[0059]
[Reaction of Reaction Formula 2- (3)]
Synthesis of 1,2-anhydro-3-O- [2,3,4-tri-O-benzyl-α-D-glucopyranosyl] -sn-glycerol (compound X)
A mixture of a crude syrup (500 mg) of Compound IX obtained in Reference Example 2 and a methanol solution (10 ml) containing 10 mg of sodium methylate was stirred for 3 hours, and Amberlyst 15 (H+And 384 mg (yield: 100%) of syrupy compound X was obtained.
[Α]twenty two D: + 38 ° (CHClThree, C 0.1),
1H-NMR (ppm): 4.90 (1H, d, J = 3.6 Hz, H-1 ′), 2.60 (1H, dd, J = 4.6, 4.8 Hz, H-1a), 2.80 (1H, dd, J = 4.5, 4.5Hz, H-1b), 3.21 (1H, m, H-2), 3.83 (1H, dd, J = 3.1, 11.8Hz, H-3a), 3.50 (1H, dd, J = 6.3, 11.8) Hz, H-3b)
[0060]
Reference example 2
[Reaction of Reaction Formula 3- (1)]
Synthesis of 1-O-palmitoyl-3-O- [2,3,4-tri-O-benzyl-α-D-glucopyranosyl] -sn-glycerol (Compound XI)
A mixture of compound X (300 mg, 0.61 mmol), palmitic acid (1 g) and cesium carbonate (650 mg) in DMF (10 ml) was stirred at 120-130 ° C. for 8 hours. The mixture was filtered and subjected to normal work-up to give 390 mg (yield: 85%) of compound XI as a waxy solid.
[Α]twenty two D: + 25 ° (CHClThree, C 0.2), mp. : 38 ° C
1H-NMR: 4.74 (1H, d, J = 3.5 Hz, H-1), 3.40 (1H, dd, J = 7.5, 10.2 Hz, H-1a), 3.77 (1H, H-1b), 4.05 (1H , m, H-2), 4.14 (1H, dd, J = 5.6, 11.7Hz, H-3a), 4.18 (1H, dd, J = 4.5, 11.7Hz, H-3b), FB-MS: 704 ( M + 1)
[0061]
[Reaction of Reaction Formula 3- (2)]
1,2-di-O-palmitoyl-3-O- [2,3,4-tri-O-benzyl-6-O-tert-butyldimethylsilyl-α-D-glucopyranosyl] -sn-glycerol ( Synthesis of compound XII)
To 10 ml of methylene chloride solution of Compound XI (200 mg, 0.26 mmol), triethylamine (0.2 ml) and N, N-dimethylaminopyridine (100 mg), tert-butyldimethylsilyl chloride (50 mg, 0.33 mmol) was stirred. 0.5 ml of methylene chloride solution was added. After stirring at room temperature for 12 hours, palmitoyl chloride (150 mg, 0.55 mmol) was added, and the mixture was further stirred for 6 hours. 0.2 ml of water was added to the mixture and stirred for 30 minutes. The organic layer was separated and subjected to normal workup. Purification by silica gel column chromatography (solvent; n-hexane: ethyl acetate = 50: 1) yielded 252 mg (yield: 86%) of syrupy compound XII.
1H-NMR (CDClThree, Ppm): 4.75 (1H, d, J = 3.6Hz, H-1), 3.53 (1H, dd, J = 6.1, 11.2Hz, H-3a), 3.74 (1H, dd, J = 5.3, 11.2Hz) , H-3b), 5.24 (1H, m, H-2), 4.40 (1H, dd, J = 3.5, 11.9Hz, H-1a), 4.20 (1H, dd, J = 5.8, 11.9Hz, H- 1b), FB-MS: 878 (M + 1)
[0062]
[Reaction of Reaction Formula 3- (3)]
1,2-di-O-palmitoyl-3-O- [2,3,4-tri-O-benzyl-α-D-glucopyranosyl] -sn-glycerol (compound I)
A methanol solution (0.9 ml) of a mixture of compound XII (200 mg, 0.18 mmol) and trifluoroacetic acid (0.1 ml) was stirred at room temperature for 12 hours. And after that, it concentrated under reduced pressure, added toluene, and concentrated repeatedly under reduced pressure. The residue was purified by silica gel column chromatography (solvent; toluene: ethyl acetate = 5: 1) to obtain 170 mg (yield: 95%) of Compound I as a waxy solid.
[Α]twenty two D: + 23 ° (c 0.2, CHClThree),1H-NMR (ppm): 4.71 (1H, d, J = 3.6 Hz, H-1), 4.42 (1H, dd, J = 3.7, 12.0 Hz, H-1a), 4.19 (1H, dd, J = 6.2) , 12.0Hz, H-1b), 3.96 (1H, t, J = 9.2Hz, H-3 '), 0.88 (6H, t, J = 7Hz, CHThree), 5.24 (1H, m, H-2), 3.55 (1H, dd, J = 5.1, 10.8Hz, H-3a), 3.74 (1H, dd, J = 6.0, 10.8Hz, H-3b), FB -MS: 1002 (M + 1)
[0063]
Example 1
[Reaction of Reaction Formula 1- (1)]
1,2-di-O-palmitoyl-3-O- [2,3,4-tri-O-benzyl-6-O- (2-bromoethoxy) -phosphinate-α-D-glucopyranosyl] -sn -Synthesis of glycerol (compound II)
2 ml of a trichloroethylene solution of triethylamine (0.12 ml) and 2-bromoethyl-phosphoryl-dichloride (100 mg) was added to a trichlorethylene solution (3.2 ml) of compound I (150 mg, 0.15 mmol). The mixture was then stirred for 12 hours at room temperature. After adding ethyl ether (5 ml) and triethylamine (0.1 ml), the mixture was refluxed for 2 hours. After cooling, the reaction mixture was acidified with 5% hydrochloric acid, extracted with ethyl ether, washed with saturated brine, and dried over anhydrous magnesium sulfate. The solution was concentrated and purified by silica gel column chromatography (solvent; chloroform: methanol = 10: 1) to obtain 141 mg (yield: 79%) of syrup-like compound II.
[Α]twenty two D: + 11.4 ° (c 0.35, CHClThree),1H-NMR (ppm): 0.88 (6H, t, CHThree), 4.72 (1H, d, J = 3.7Hz, H-1 '), 4.40 (1H, dd, J = 3.3, 12.1Hz, H-1a), 4.19 (1H, dd, J = 6.1, 12.1Hz, H-1b), 5.23 (1H, m, H-2), 3.95 (1H, t, J = 9.3Hz, H-3 '), 4.10 (2H, m, -CH2-O-P), 3.42 (2H, t, -CH2-Br), FB-MS: 1188 (M + 1)
[0064]
[Reaction of Reaction Formula 1- (2)]
1,2-di-O-palmitoyl-3-O- [2,3,4-tri-O-benzyl-6-O- (2-trimethylaminoethoxy) -phosphinate-α-D-glucopyranosyl]- Synthesis of sn-glycerol (Compound III)
Compound II (100 mg, 0.08 mmol) was dissolved in 3 ml of a mixed solution of chloroform-2-propanol-DMF (3: 5: 5) saturated with trimethylamine (gas), and then heated at 70 ° C. for 8 hours. Then cooled and silver carbonate was added. The reaction mixture was refluxed with heating (70 ° C.) for 1 hour and then cooled to room temperature. And filtered through celite. The filtrate was concentrated, and the residue was purified by silica gel column chromatography (solvent; chloroform: methanol = 1: 1) to obtain 61 mg of syrup-like compound III (yield: 62%).
[Α]twenty two D: + 30.0 ° (c 0.04, CHClThree),1H-NMR (ppm): 0.88 (6H, t, CHThree), 3.17 (9H, S, N (CHThree)Three), 3.92 (1H, t, J = 9.3Hz, H-3 '), 4.18 (1H, dd, J = 6.0, 12.1Hz, H-1b), 4.39 (1H, dd, J = 3.3, 12.1Hz, H-1a), 5.23 (1H, m, H-2), FB-MS: 1175 (M + 1)
[0065]
[Reaction of Reaction Formula 1- (3)]
1,2-di-O-palmitoyl-3-O- [6-O- (2-trimethylaminoethoxy) -phosphinate-α-D-glucopyranosyl] -sn-glycerol (compound IV) (GGPL- Synthesis of I)
Compound III (50 mg, 0.04 mmol) and palladium hydroxide [Pd (OH)2(50 mg) was treated with hydrogen gas at room temperature for 12 hours (methanol: water: acetic acid = 10: 1: 1 mixed solvent, 5 ml). The reaction solution was filtered and the solvent was concentrated to obtain 35 mg (yield: 91%) of Compound IV (GGPL-I) as a waxy solid.
[Α]twenty two D: 24.9 ° (c 0.06, CHClThree: MeOH = 2: 1),
FB-MS 897 (M + 1)
1H-NMR (DMSO-d6): 3.13 (9H, S, N (CHThree)Three), 3.53 (1H, dd, J = 5.4, 11.0Hz, H-3a), 3.68 (1H, dd, J = 5.2, 11.0Hz, H-3b), 4.32
(1H, dd, J = 3.2, 11.8Hz, H-1a), 4.14 (1H, dd, J = 6.7, 11.8Hz, H-1b), 4.65 (1H, d, J = 3.6Hz, H-1 ' )
[0066]
[Effects of the present invention]
The production method of the present invention provides a novel production method capable of chemically producing a phosphorylcholine-containing glyceroglycolipid compound that has been obtained only naturally from a glyceroglycolipid compound derivative having a hydroxyl group protected. To do.
Further, the present invention relates to 1,2-di-O-palmitoyl-3-O- [2,3,4-tri-O-benzyl-6-O- (2-trimethylaminoethoxy)- It relates to novel compounds comprising phosphinate-α-D-glucopyranosyl] -sn-glycerol.
Claims (2)
第2段階において、前述のようにして得られた化合物IIとトリメチルアミンとを溶媒中で反応させて、構造式III
【化3】
[但し、構造式IIIにおける、Aは前述と同様である。]で示される化合物IIIを合成し、最後に、
第3段階において、前述のようにして得られた化合物IIIを水添触媒の存在下に水素と接触させて構造式IV
In the second stage, the compound II obtained as described above and trimethylamine are reacted in a solvent to give the structural formula III
[Chemical 3]
[However, A in Structural Formula III is the same as described above. A compound III represented by the following formula:
In the third stage, the compound III obtained as described above is contacted with hydrogen in the presence of a hydrogenation catalyst to give the structural formula IV
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP05452495A JP3717962B2 (en) | 1994-03-18 | 1995-03-14 | Method for producing glyceroglycolipid compound |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6-48670 | 1994-03-18 | ||
| JP4867094 | 1994-03-18 | ||
| JP05452495A JP3717962B2 (en) | 1994-03-18 | 1995-03-14 | Method for producing glyceroglycolipid compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07304789A JPH07304789A (en) | 1995-11-21 |
| JP3717962B2 true JP3717962B2 (en) | 2005-11-16 |
Family
ID=26388974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP05452495A Expired - Fee Related JP3717962B2 (en) | 1994-03-18 | 1995-03-14 | Method for producing glyceroglycolipid compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3717962B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180074804A (en) | 2009-06-04 | 2018-07-03 | 고쿠리츠칸센쇼켄쿠죠 | Vaccine for mycoplasma infection |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5212973B2 (en) * | 2005-08-22 | 2013-06-19 | 国立大学法人名古屋大学 | Glycolipid derivative synthesis intermediate and production method thereof, and glycolipid derivative and production method thereof |
| JP5252468B2 (en) * | 2007-06-27 | 2013-07-31 | エム バイオ テック株式会社 | Method for synthesizing mycoplasma pneumoniae specific antigen glycolipid |
-
1995
- 1995-03-14 JP JP05452495A patent/JP3717962B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180074804A (en) | 2009-06-04 | 2018-07-03 | 고쿠리츠칸센쇼켄쿠죠 | Vaccine for mycoplasma infection |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07304789A (en) | 1995-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3183506B2 (en) | Improved sucrose-6-ester chlorination method | |
| Cottaz et al. | Parasite glycoconjugates. Part 1. The synthesis of some early and related intermediates in the biosynthetic pathway of glycosyl-phosphatidylinositol membrane anchors | |
| JP7598148B2 (en) | Method for producing repeating disaccharides and their oligomers in oligosaccharide synthesis | |
| JP3717962B2 (en) | Method for producing glyceroglycolipid compound | |
| KR900006213B1 (en) | N-glycolyl-neuramic acid-containing glycolipid and its preparation method | |
| WO1995032955A1 (en) | 7-fluoro-2, 3-didehydrosialic acid and intermediate for synthesis thereof | |
| JPH0582393B2 (en) | ||
| JPH11255794A (en) | Fullerene derivative and its production | |
| CN101553477A (en) | Process for preparing aldonic acid and derivatives thereof | |
| JP3110474B2 (en) | Oligosialyl-1,2-dialkyl-Sn-glycerol and synthetic intermediates thereof | |
| JP5305697B2 (en) | Method for producing α-D-mannopyranoside derivative | |
| JP5328183B2 (en) | Method for producing glucoside ester derivative | |
| EP0819697A2 (en) | 1-C-perfluoroalkyl glycosides, method of preparation and use | |
| JP3163359B2 (en) | Sulfated oligosaccharide compounds | |
| JPS6053039B2 (en) | N-Acetyl/Iramic acid derivative and method for producing the same | |
| CN115636848B (en) | Method for synthesizing phosphorylcholine compound by one-pot method | |
| JPH0425275B2 (en) | ||
| JP3837876B2 (en) | Azidohalogenobenzyl derivatives and methods for protecting hydroxyl groups | |
| JPH0536441B2 (en) | ||
| JP2753353B2 (en) | Analogs of sialosyl cholesterol and method for producing the same | |
| JPH04500677A (en) | A special method for the synthesis of novel dithiocarbamate esters by replacing the hydroxylated sites of mono- or polyhydroxylated molecules, the products obtained by this method and their applications. | |
| JPH07116206B2 (en) | Novel sialic acid derivative | |
| JP2701035B2 (en) | Novel amino sugar derivative and method for producing the same | |
| Podvalnyy et al. | A Facile Synthesis of 1, 3, 4, 6-Tetra-O-acetyl-2-deoxy-2-trifluoroacetamido-β-d-glucopyranose | |
| JP2581029B2 (en) | Novel method for producing sialic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050308 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050420 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050617 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050617 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050901 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090909 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100909 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100909 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110909 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120909 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120909 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130909 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |